iRhythm Holdings (IRTC) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.58
- Estimate
- $0.04
- Surprise
- +1258.0%
- Revenue (period 2026-06-30)
- $224.2M
- Score at report (before → after)
- 6.1 → 6.2/10
Revenue source: xbrl.
How the report landed
iRhythm Holdings (IRTC) beat the $0.04 estimate with adjusted EPS of $0.58 — a large 1258.0% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.1/10) to Sell at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IRTC Sell at 5.7/10.
4 of the last 4 quarters beat the estimate; this quarter's +1258.0% surprise compares with a +448.1% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (4/4)
What argues against it
- Concentration risk — Product: iRhythm Services
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8)
- Leverage penalty (D/E 3.9): -1.5
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $110.82
- Price target
- $153.24
- Stop
- $104.68
- Upside to target
- +38.3%
- Reward-to-risk
- 4.9:1
Risk check: RSI 24 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-24 — shown for context, not personalized investment advice.
IRTC at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $3.68B
- P/E (fwd)
- 92.1
- 52-week range
- $100.85–$212.00
- Off 52-week high
- 47.7%
- RSI (14)
- 24
- Volume vs avg
- 0.07×
- Score today
- 5.7/10